Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and immune complex formation. [1] [2] [3] [4] [5] [6] [7] Immune-mediated nephritis caused by deposition of pathogenic autoantibodies and immune complex in the glumeruli is the leading cause of mortality and morbidity in this disease. The studies of spontaneous lupus nephritis (SLN) in mouse models and experimental anti-GBM disease have provided valuable insights into the underlying mechanisms of human lupus nephritis. [8] [9] [10] [11] [12] [13] [14] The experimentally induced anti-GBM model has proven to be a particularly useful approach for studying end-organ susceptibility to immune-mediated damage. [9] [10] [11] [12] Our earlier studies have shown that NZW mice exhibit increased susceptibility to experimental anti-GBM-induced glomerulonephritis (EAG), compared with C57BL/6 (B6). 10 Instead of performing a traditional mapping study to identify the responsible genetic loci, we took advantage of the fact that several NZW/NZM2410-derived 'Sle' susceptibility loci had already been bred onto the normal B6 background as congenic intervals. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] One such lupussusceptibility interval is Sle3 z on chromosome 7. 19, 22, 26 Unlike the other B6.Sle congenic strains tested, B6.Sle3 z mice (bearing the NZM2410/NZW-derived 'z' allele of Sle3 on the relatively normal B6 background) exhibit increased susceptibility to EAG, compared with B6. 27 Further fine mapping using recombinant subcongenics bearing progressively narrower subintervals of Sle3 showed the susceptibility genes to be located between D7mit157 and D7mit158 on chromosome 7, 27 an interval harboring the kallikrein cluster of genes. Microarray and real-time PCR studies indicated that several EAGsusceptible strains (such as 129/svJ, NZW and DBA/1) as well as the B6.Sle3 congenic strain had significantly reduced renal expression of kallikreins, compared with B6 and BALB/c controls, following anti-GBM challenge. Furthermore, sequence comparison of several klk genes indicated that nephritis-prone mouse strains and patients with lupus nephritis possessed different klk alleles, compared with controls. 27 The above-mentioned studies suggested that kallikreins might be renoprotective in immune-mediated nephritis. Indirect evidence for this was provided by showing that bradykinins (which are generated by kallikreins) can be renoprotective, although bradykinin receptor blockade aggravated anti-GBM-induced nephritis. 27 The earlier studies did not address if kallikreins themselves could modulate disease when deliberately administered to nephritis-susceptible mice. In this communication, we directly test if systemic delivery of kallikreins is renoprotective against autoantibody-induced nephritis, using B6.Sle3 z congenic mice as the disease model.
Materials and methods

Construction and preparation of recombinant adeno-mklk1
The recombinant adenoviral Ad-GFP vector (AdEasy vector system, Stratagene, La Jolla, CA, USA) was used for making the Ad-mklk1 construct, following the vendor's instructions. Briefly, the mouse klk1 gene coding region (786 bp) was PCR amplified from the B6 strain using the following primers: forward 5 0 -AGCGTCG ACACCATGAGGTTCCTGATC-3 0 , reverse 5 0 -AGCCTCGA GGTCATTTTCAGCCATAG-3 0 , and inserted into the multicloning site of pShuttle-IRES-hrGFP vector. Once constructed, the shuttle vector was linearized with PmeI and co-transformed into BJ5183 competent cells together with pAdEasy-1, a supercoiled viral DNA plasmid. Transformants were selected for kanamycin resistance, and recombinants containing mKlk1 insert were subsequently identified by restriction digestion. Once a recombinant was identified, it was produced in bulk using the recombination-deficient XL10-Gold strain. Purified recombinant Ad-mklk1 plasmid DNA was digested with PacI to expose its inverted terminal repeats, and then used to transfect AD-293 cells, in which deleted viral assembly genes are complemented in vivo. Ad-mklk1 was amplified and purified from these cells, and the titer of recombinant virus was measured by plaque assays. The Ad-GFP vector was used as a control.
Animal studies C57BL/6 (B6) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). B6.Sle3 z is a congenic stain bearing the lupus-susceptibility interval, Sle3 z . 15, 19, 26 All mice were maintained in a specific pathogen-free colony. Two to three-month-old females were used for all studies. To induce EAG, 10 mice from each strain were sensitized on day 0 with rabbit IgG (250 mg per mouse, intraperitoneally), in adjuvant. On day 3, mice of each strain were randomly divided into two groups of five mice each. One group received recombinant Ad-mklk1 virus through tail vain injection (1 Â 10 7 PFUs per mouse) and another group received the same dose of Ad-GFP vector as control. On day 5, all mice were challenged (intravenously) with rabbit anti-GBM IgG (200 mg per 25 g of body weight). Twenty-four-hour urine and serum samples were collected from all mice on days 0, 7, 14 and 21, for measuring proteinuria, serum BUN (blood urea nitrogen) and kallikrein activity. All animals were killed on day 21, and the kidneys were processed for histopathological examination by light microscopy. Five mice were included in each experimental group.
Detection of Klk1 expression in serum by western blotting
Serum samples were collected from each experimental mouse at days 0, 7, 14 and 21. Sera were diluted 1:10 with phosphate-buffered saline and protein concentration was measured using the BCA protein assay kit (Pierce, Rockford, IL, USA). A volume of 10 mg of serum protein from each sample was subjected to SDS-polyacrylamide gel electrophoresis and transferred to nylon membrane for western blot analysis using a rabbit anti-mouse kallikrein-1 antibody (1:1000), as described. 27 Immunoreactivity was detected by chemiluminescence (Pierce).
Detection of urine kallikrein excretion by enzymatic activity assay
Twenty-four-hour urine samples were collected from each mouse using metabolic cages on days 0, 7, 14 and 21. Total urinary kallikrein enzymatic activity was measured using the synthetic chromogenic substrate HD-Val-Leu-Arg-pNA (S-2266), as described by Moodely et al. 28 Briefly, 50 ml of mouse urine sample was added to 50 ml of assay buffer (0.2 M Tris-HCl, pH 8.2, containing 300 mg l À1 SBTI and 375 mgl À1 EDTA) and incubated at 37 1C for 30 min. Then, 50 ml of S-2266 was added and incubated for 3 h at 37 1C. The plate was read at 405 nm. A standard curve was constructed using purified human urinary kallikrein (HUK, Calbiochem, San Diego, CA, USA). The amount of total protein in the urine was measured using the BCA Protein assay kit (Pierce).
Assessing renal disease
Twenty-four-hour urine samples were collected from experimental mice on days 0, 7, 14 and 21, using metabolic cages, with free access to drinking water. Urinary protein concentration was determined using the Coomassie Plus protein assay kit (Pierce). Serum was collected on day 14, for measuring BUN, using a urea nitrogen kit (Sigma-Aldrich, St Louis, MO, USA). Threemicrometer sections of formalin-fixed, paraffin-embedded kidney tissues were cut and stained with hematoxylin and eosin and periodic acid-Schiff. All sections were examined in a blinded manner, for any evidence of pathology in the glomeruli, tubules or interstitial areas, as described earlier. 12 The severity of glomerulonephritis (GN) was graded on a 0-4 scale as follows: 0, normal; 1, mild increase in mesangial cellularity and matrix; 2, moderate increase in mesangial cellularity and matrix, with thickening of the GBM; 3, focal endocapillary hypercellularity with obliteration of capillary lumina and a substantial increase in the thickness and irregularity of the GBM; and 4, diffuse endocapillary hypercellularity, segmental necrosis, crescents and hyalinized end-stage glomeruli. The severity of tubulointerstitial nephritis was graded on a 0-4 scale, on the basis of the extent of tubular atrophy, inflammatory infiltrates and interstitial fibrosis, as detailed earlier. 29 
Statistics
Results are expressed as mean ± s.e.m. Data were analyzed using the unpaired Student's t-test or analysis of variance, with the use of GraphPad Prism 5.0 software (San Diego, CA, USA). Values were considered significantly different if Po0.05.
Results
Expression of kallikrein in B6 and B6Sle3 z mice after klk1 gene delivery Following intravenous injection of an adenovirus encoding the mouse klk1 gene, recombinant kallikrein levels in mouse sera and tissues were assayed by western blot using a rabbit anti-mKlk1 antibody. All B6 and B6.Sle3 z mice receiving Ad-mklk1 expressed significantly elevated kallikrein levels in their blood and liver, but not in the kidneys or spleen (Figure 1 and data not shown), compared with the control mice. Figure 1a shows a representative western blot. Klk1 expression reached its peak on day 7 (that is, 5 days after Ad-mklk1 injection) and then started to decrease. The expression of Klk1 in mouse serum was still detectable on the day of killing (day 21). Mice receiving Ad-GFP vector control did not have detectable kallikrein expression in their serum. Kallikrein excretion was also detected in the urine of B6.Sle3 z mice receiving Ad-mklk1 injection on days 7, 14 and 21 (3.35 ± 2.23, 13.38 ± 6.86 and 7.44 ± 4.42 mg per 24 h, respectively), compared with the vector control group (0.69 ± 0.43, 0.49 ± 0.3 and 0.95 ± 0.66 mg per 24 h, respectively) (P-values: 0.03, 0.007 and 0.05, respectively), as summarized in Figure 1b .
Effect of kallikrein gene delivery on proteinuria and serum BUN As expected, the B6.Sle3 z mice in the control group (receiving Ad-GFP vector injection) developed high levels of proteinuria on day 14 (19.2±2.1 mg per 24 h) and day 21 (9.7 ± 2.5 mg per 24 h), after anti-GBM Ab challenge. In contrast, B6.Sle3 z mice in the klk1 gene delivery group (receiving Ad-mklk1 injection) showed significantly reduced proteinuria on days 14 and 21 (3.2 ± 0.6 and 2.6 ± 0.3 mg per 24 h, respectively) compared with the vector control group (Po0.001, n ¼ 5), as diagramed in Figure 2a . There was no significant increase in proteinuria in unchallenged B6 mice receiving the adenoviral vector (data not shown). Likewise, on day 14 after anti-GBM challenge, the serum BUN levels in B6.Sle3 z mice injected with Ad-GFP control vector reached 33.9 ± 4.0 mg ml À1 . However, B6.Sle3 z mice treated with recombinant Ad-mklk1 showed significantly lower serum BUN (18.5 ± 4.6 mg ml À1 ) compared with the vector control mice (P ¼ 0.004), as shown in Figure 2b . Unchallenged B6 mice treated with Ad-GFP or Ad-mklk1 showed low levels of serum BUN, which was similar to the levels in klk1-treated B6.Sle3 z mice (data not shown).
Effect of kallikrein gene delivery on renal histology
Histological analysis of the kidneys confirmed that the klk gene delivery attenuated histological GN induced by anti-GBM challenge (Figure 3 ). B6.Sle3 z mice receiving Ad-GFP vector showed moderate-to-severe GN with a score of 2.7 ± 0.5, whereas the Ad-klk1-injected B6.Sle3 z mice showed ameliorated glomerular disease with a GN score of 1.4±0.2 (P ¼ 0.02) (Figure 3a ). The marked GN in the control group was also accompanied by significant glomerular proliferation and crescent formation, as exemplified by representative slides depicted in Figure 3b . Collectively, the above functional readouts and histological findings indicate that the deliberate administration of kallikreins systemically has the capacity to dampen autoantibody-initiated GN. In terms of the proteinuria, BUN and renal pathology, the kallikreintreated mice did not differ significantly from unmanipulated mice (that is, not challenged with anti-GBM Abs). [10] [11] [12] 
Discussion
The EAG experimental model of immune-mediated nephritis has emerged as a useful tool for dissecting out the molecular and genetic basis of lupus nephritis. 9 The finding that B6.Sle3 z congenic mice are more sensitive to EAG than the B6 controls has fueled studies aimed at identifying potential renal-intrinsic factors that may govern this phenotype. 27 One key molecular difference that clearly distinguishes the EAG-sensitive strains from the resistant strains is their renal kallikrein expression levels upon anti-GBM Ab challenge. 27 Interestingly, the klk gene cluster is located within the Sle3 lupus-susceptibility interval on murine chromosome 7, with interesting sequence polymorphisms, raising the possibility that these could be the genes responsible for the observed renal phenotypes in this strain. The impaired renal expression of kallikreins in B6.Sle3 z and other EAG-sensitive strains suggests that klk may play a protective role against nephritis. 27 These earlier findings resonate well with previous genetic and pharmacological studies that also show a renoprotective role for kallikreins and bradykinins in nephritis following other types of insults. [30] [31] [32] [33] [34] [35] [36] [37] [38] In this study, we offer the first demonstration that deliberate kallikrein gene delivery can indeed protect mice against anti-GBM-induced nephritis. After systemic delivery of adenovirus containing mouse klk1, immunoreactive mouse klk1 was detected in the serum and urine of Ad-klk1-injected B6 and B6.Sle3 z mice, indicating that recombinant mouse Klk1 (most likely of serum origin) was being excreted from the kidneys. Importantly, the klk1 gene transfer markedly reduced urinary protein, serum BUN levels and glomerular inflammation in the anti-GBM-challenged B6.Sle3 z mice, showing that kallikreins can indeed be renoprotective in antibody-mediated nephritis. Although only Klk1 was used in this study, it is most likely to be representative of all kallikreins given that the genes in this family are evolutionarily conserved and have 67-91% primary sequence identity. 43 A second rationale for using Klk1 relates to the fact that Klk1 gene transfer has earlier been shown to successfully ameliorate renal disease in other animal models. 35 As reported by others, kallikreins may be exerting a protective role in nephritis by modulating several different parameters, including local blood pressure, the inflammatory milieu, redox balance and/or signaling within various cell types. [39] [40] [41] [42] [43] [44] Kallikreins and kinins have also been shown to improve renal function by increasing the glomerular filtration rate and renal blood flow. 31, 45 Anti-GBM Abs directed to antigens on the glomerular basement membrane can trigger a rapid inflammatory reaction characterized by the accumulation of polymorphonuclear leukocytes and mononuclear cells. 46 It has been well documented that anti-GBM Ab-induced nephritis is associated with oxidative stress in the form of reactive oxygen species, which in turn can activate MAPKs (mitogen-activated protein kinases), particularly p38 MAPK and JNK, and also induce apoptosis. [47] [48] [49] [50] [51] [52] In this context, it is worth noting that others have reported that kallikreins and kinins could also act as antioxidant and anti-inflammatory agents through the suppression of oxidative stress, monocyte/macrophage recruitment and renal cell apoptosis. 34, 53 Others have observed that the activation of the kinin B2 receptor by kallikreins and kinins can mobilize intracellular Ca2 þ , enhance intracellular nitric oxide synthase activity and thus nitric oxide production. 34, 35, 42, 53 The increased bioavailability of nitric oxide could in turn counter oxidative stress, MAPK activation and ongoing inflammation. [34] [35] [36] [37] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Hence, the renoprotective effect of kallikreins in Ab-mediated nephritis could potentially have been mediated through a wide variety of molecular mechanisms operating in parallel.
It is also worth considering the interplay of kallikreins/kinins with another multimolecular enzyme system, the renin-angiotensin system. It is now apparent that both these systems interface at multiple levels. [54] [55] [56] [57] [58] Both angiotensin and kinin peptides are metabolized by many different shared peptidases, including prolylcarboxypeptidases. This interaction, along with the roles of angiotensin-converting enzyme, crosstalk between bradykinin and angiotensin action, and the opposing effects of activation of the ANG II receptors 1 and 2 support a hypothesis that these two systems might counterbalance each other. Finally, there is evidence that angiotensinconverting enzyme inhibitors, which are also therapeutically effective in lupus nephritis, could function in part by potentiating the effect of bradykinin and its analogs on B2 receptors independently of blocking peptide metabolism. Hence, some of the documented impacts of the renin-angiotensin system on nephritis need to be re-evaluated in terms of how they might impact kallikrein/kinin activity.
The observation that the NZW-derived Sle3 z lupussusceptibility locus confers susceptibility to SLN raises the interesting possibility that polymorphisms in Klk may also confer susceptibility to SLN. Resonating well with this observation in the mouse is the finding that single-nucleotide polymorphisms in human KLK genes may also be associated with lupus nephritis in patients. 27 Efforts are in progress to evaluate if long-term modulation of Klk levels in vivo can impact the severity of SLN. This study provides significant insights regarding the role of the kallikrein/kinin system in mediating protection against antibody-mediated nephritis. These studies also raise the interesting possibility that different end-organs may harbor an arsenal of molecules with anti-inflammatory and/or disease-modulating potential as safeguards against immune-mediated disease.
